ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company
developing genetically-targeted therapies for cardiovascular diseases,
today announced that Robert E. Conway, has been appointed to the
Company’s Board of Directors. He will serve on the Audit and
Compensation Committees of the Board of Directors.
Mr. Conway has over 30 years of executive leadership experience in the
pharmaceutical and biotechnology industries. From 1999 to 2012, he
served as the Chief Executive Officer and member of the Board of
Directors of Array BioPharma, a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Prior to joining Array, Mr. Conway was the Chief Operating Officer and
Executive Vice President of Hill Top Research, Inc., from 1996 to 1999.
There he managed a network of company-owned research centers, conducting
clinical trials for pharmaceutical and biotechnology companies. From
1979 until 1996, Mr. Conway held various executive positions with
Corning, Inc., including Corporate Vice President and General Manager of
Corning Hazleton, Inc., a contract research organization. Mr. Conway
serves as the Chairman of Wall Family Enterprise, a leading library and
education supplies company. He is on the Board of Directors of PRA
International, Inc. and eResearch Technology, Inc. In addition, Mr.
Conway is a member of the Strategic Advisory Committee of Genstar
Capital, LLC.
“We are honored to have Bob join the ARCA Board of Directors,” said Dr.
Michael R. Bristow, President and Chief Executive Officer of ARCA. “With
his significant experience in leading both drug development efforts and
companies in the biopharmaceutical sector, Bob will be a valuable
addition to the ARCA Board as we continue the development of Gencaro and
look to deliver value to our stockholders.”
“I am delighted to join the Board of ARCA at this important point in its
development, both for the company and for the cardiology patients we
hope to serve,” said Mr. Conway. “We believe there is an unmet medical
need for new atrial fibrillation treatments. The GENETIC-AF trial,
conducted with the collaboration of Medtronic, will hopefully provide
important new data for the atrial fibrillation community.”
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies
for cardiovascular diseases. The Company's lead product candidate,
GencaroTM (bucindolol hydrochloride), is an investigational,
pharmacologically unique beta-blocker and mild vasodilator being
developed for atrial fibrillation. ARCA has identified common genetic
variations that it believes predict individual patient response to
Gencaro, giving it the potential to be the first genetically-targeted
atrial fibrillation prevention treatment. ARCA has a collaboration with
Medtronic, Inc. for support of the Phase 2B portion of the GENETIC-AF
trial. For more information please visit www.arcabiopharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements" for purposes of
the safe harbor provided by the Private Securities Litigation Reform Act
of 1995. These statements include, but are not limited to, statements
regarding the potential impact of the GENETIC-AF trial, the potential
for genetic variations to predict individual patient response to
Gencaro, Gencaro’s potential to treat atrial fibrillation, future
treatment options for patients with atrial fibrillation, and the
potential for Gencaro to be the first genetically-targeted atrial
fibrillation prevention treatment. Such statements are based on
management's current expectations and involve risks and uncertainties.
Actual results and performance could differ materially from those
projected in the forward-looking statements as a result of many factors,
including, without limitation, the risks and uncertainties associated
with: the Company's financial resources and whether they will be
sufficient to meet the Company's business objectives and operational
requirements; results of earlier clinical trials may not be confirmed in
future trials, the protection and market exclusivity provided by the
Company’s intellectual property; risks related to the drug discovery and
the regulatory approval process; and, the impact of competitive products
and technological changes. These and other factors are identified and
described in more detail in ARCA’s filings with the SEC, including
without limitation the Company’s annual report on Form 10-K for the year
ended December 31, 2012, and subsequent filings. The Company disclaims
any intent or obligation to update these forward-looking statements.
Copyright Business Wire 2013